Global Boardrooms Sceptical About Potential For UK To Be Lifesciences Superpower
The UK has the potential to fulfill its ambition of being a global superpower in life sciences, but it must not get lost in an echo chamber, says a senior MSD executive.
You may also be interested in...
Companies that are in earlier stages of the drug development process will benefit most from the UK regulator's new pathway for innovative medicines.
The UK drug regulator, the MHRA, has approved its first product under Project Orbis, the US-led international regulatory collaboration scheme it joined four months ago to speed up access to promising cancer medicines.
More political support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.